15 Mental Health Groups Just Defined Psychedelic Therapy. Ketamine Is Not in It

15 Mental Health Groups Just Defined Psychedelic Therapy. Ketamine Is Not in It

Fifteen of the largest mental health organizations in the country published a shared definition of psychedelic-assisted therapy on November 2. The definition has six requirements.

Ketamine is not named once. Neither is esketamine, psilocybin, MDMA, telehealth or at-home dosing. Ketamine is the one treatment in this space already delivered at scale in American clinics, and it is absent from the document that defines the category.

Principle 4 ties care to licensure standards, codes of ethics and defined scopes of practice. Your carrier reads those too. The HealingMaps GPO is the first built for the ketamine industry. Members get 15 to 20 percent off malpractice and liability premiums, 40 percent or more off medical supplies, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free and carries no obligation. Ask what your clinic qualifies for →

Key Takeaway Detail
Who signed 15 national groups, including both American Psychiatric and American Psychological Associations
Who wrote it Workgroup co-convened by the CEOs of the APA and the National Association of Social Workers
The definition Six parts, including continuous in-person monitoring and post-treatment integration
Substances named None. Zero mentions of ketamine, psilocybin or MDMA anywhere in the text
The real line it draws Between supervised in-clinic dosing and anything delivered without a clinician present
Binding? No. But these groups write the ethics codes and shape credentialing, which is slower pressure
Two P&L items Principle 2 on access regardless of insurance, Principle 7 on conflict disclosure

The six-part definition

The Alliance describes psychedelic-assisted therapy as a comprehensive, clinically appropriate and evidence-based treatment. Then it lists what the treatment has to include.

Requirement What it means in a clinic
Meticulous assessment and patient selection A real screen, with people turned away
Extensive preparation before dosing Billable or not, a session happens before the medicine
Continuous in-person monitoring A clinician in the room, the whole time
Intervention during the session Someone qualified to act, not just observe
Integration Structured work after the dose, not a follow-up email
Post-treatment services A care pathway that continues

Read as a checklist, it describes a staffed in-clinic practice. A well-run IV or IM ketamine clinic with a preparation visit and integration sessions clears most of it already.

An at-home model does not clear the third line, by design. That is the line the document draws, and it drew it without naming anybody.

Who actually signed this

The signatory list is the reason to pay attention. It is not an advocacy coalition.

The American Psychiatric Association and the American Psychological Association are both on it. So is the National Association of Social Workers. So are NAMI, Mental Health America, the Kennedy Forum, the American Foundation for Suicide Prevention, the National Council for Mental Wellbeing and the National Association for Behavioral Healthcare.

Those bodies write the ethics codes your therapists are bound by. They run the continuing education your prescribers need. They get called first when a state legislature drafts a scope-of-practice bill.

The workgroup behind the document was co-convened by Dr. Marketa Wills, CEO of the American Psychiatric Association, and Dr. Anthony Estreet, CEO of the National Association of Social Workers.

Three principles that touch the business

Most of the eight principles are what you would expect. Science-based innovation, workforce development, responsible communication. Three of them have teeth.

Principle 2 goes after cash-pay. It says payment models must foster inclusive access regardless of insurance coverage. That is a professional-ethics argument against a cash-only business model, made by the organizations that credential the clinicians delivering it.

Principle 4 is about scope. It requires alignment with current licensure standards, codes of ethics and defined scopes of practice. NASW co-convening the workgroup matters here. Social workers deliver a large share of the therapy hours in ketamine clinics, and scope is the live fight.

Principle 7 asks for conflict disclosure. It commits the signatories to disclosing and managing real and perceived conflicts of interest. Applied outward, that reaches clinics with ownership ties to telehealth platforms or compounding pharmacies.

How much weight to give it

Not much, immediately. This is a non-binding vision statement from a voluntary coalition, and it is explicitly prospective. The vision is conditioned on these treatments clearing standard regulatory review first, which has not happened for psilocybin or MDMA.

Nothing here changes a license, a payer policy or a state rule this week.

What it changes is the reference text. A state board, a malpractice carrier or a credentialing committee needing a definition of psychedelic-assisted therapy now has one with fifteen national signatures on it. There is no competing document.

We do not know whether the Alliance intended the definition to reach ketamine. The document does not say, and the omission could be caution rather than exclusion.

What a clinic can do with this

Read the six requirements as an audit of your own protocol. Find the one you cannot document.

Most clinics can show the screen and the monitoring. Fewer can show integration as a defined part of the care pathway, rather than something a therapist does if there is time.

That is the gap worth closing first, because it is the one a credentialing committee would ask about.

We covered the parallel question of who decides who delivers psychedelic therapy. For the state of clinical consensus, see two expert panels that reached opposite conclusions. Patients looking for supervised care can start with our directory of verified ketamine clinics.

This article is for informational purposes and is not legal, medical or business advice. The CEO Alliance document is a non-binding statement of principles and does not carry regulatory force.

Healing Maps Editorial Staff

Healing Maps Editorial Staff

View all posts by Healing Maps Editorial Staff

The Healing Maps Editorial Team has decades of experience across all facets of the psychedelic industry. From assessing studies and clinic research, to working with clinician's and clinics, we help provide data-backed information to psychedelic-curious individuals across the globe.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Explore Psychedelic Therapy Regions